Overview

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure

Status:
Active, not recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
To study the safety and efficacy of CG0070, an oncolytic virus expression GMCSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.
Phase:
Phase 3
Details
Lead Sponsor:
Cold Genesys, Inc.